Close Menu

Serimmune: Noah Nasser, Bill Welch

Aug 06, 2019

Goleta, California-based Serimmune has appointed Noah Nasser as CEO and Bill Welch to its board of directors.

Prior to Seriummne, Nasser served as chief commercial officer at Human Longevity. Before working at Human Longevity, Nasser served as chief commercial officer at Counsyl. In addition, he held leadership positions at AltheaDx and Verinata Health. 

Welch is currently a venture partner at Illumina Ventures. Before joining Illumina Ventures, Welch served as CEO at Trovagene. Prior to Trovagene, Welch was president and CEO at Sequenom. Before working at Sequenom, Welch served as CCO at Monogram Biosciences. Prior to Monogram, Welch held progressive management positions at Abbot Laboratories. 

More Like This

Jan 15, 2020

Tempus: Ari Caroline, Iker Huerga

Tempus has hired Ari Caroline as senior VP of health strategy and Iker Huerga as VP of data engineering and strategy. Both founded healthcare artificial intelligence firm Da'At AI, an early-stage startup that Tempus recently acquired the entire team of. Prior to launching Da'At, Caroline was chief analytics officer at Memorial Sloan-Kettering Cancer Center in New York, while Huerga served as director of engineering and applied machine learning for MSK.

Jan 15, 2020

Illumina: Jay Flatley

Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.

Jan 14, 2020

Myriad Genetics: Thomas Slavin

Thomas Slavin will be senior VP of medical affairs at Myriad Genetics' oncology division. Starting March 2, he will report to Nicole Lambert, president of Myriad Oncology, and be in charge of Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Slavin is board certified in clincial genetics, medical diagnostics, and pediatrics, and most recently was an assistant professor in City of Hope National Medical Center's medical oncology & therapeutics research and population sciences division. 

Jan 13, 2020

T2 Biosystems: Tony Pare

T2 Biosystems has promoted Tony Pare to the newly created position of chief commercial officer, effective immediately. Pare previously served as vice president and general manager of T2 Biosystems' international business. Prior to that, he held senior business development positions at Haemonetics and Hemanext.

Jan 13, 2020

Spartan Bioscience: Dirk Sibbing; Gilles Montalescot; Marco Valgimigli; Davide Capodanno

Spartan Bioscience has establishd a scientific advisory board in Europe. The members are Dirk Sibbing, an inverventional cardiologist and professor of cardiology at Ludwig-Miximilians University in Munich; Gilles Montalescot, a professor of cardiology at the University of Paris VI, and director of the cardiac care unit at Pitié-Salpêtrière Hospital, Paris; Marco Valgimigli, associate professor of cardiology and senior interventional cardiology at Inselspital Universitätsspital in Bern, Switzerland; and Davide Capodanno, associate professor of cardiology at the University of Catania, Italy, and interventional cardiologist, Azienda ""Policlinico-Vittorio Emanuele" in Catania. The company added that a North American team will be announced in March at the American College of Cardiology conference. 

 
Jan 13, 2020

Foundation Medicine: Ritesh Khullar

Ritesh (Tesh) Khullar has been appointed as chief commercial officer of Foundation Medicine, effective Jan. 20. He joins the Roche subsidiary from Flatiron Health, where he was responsible for leading and scaling provider service offerings. Prior to that, he was the national VP and general manager of sales and account management at McKesson Specialty Health. He also held various roles at Oncology Therapeutics Network. Khullar holds an MBA from the University of San Francisco and a BA in history with a minor in computer science and engineering, political science, and law and society from the University of California, San Diego.

Jan 13, 2020

Twist Bioscience: Patrick Weiss, Bill Banyai

Twist Bioscience has promoted Patrick Weiss to chief operating officer from senior VP of R&D and general manager of data storage. It has appointed Bill Banyai as senior VP of advanced development and general manager of data storage.

Before helping to build Twist's operational infrastructure, Weiss served as President and CEO of Operon Biotechnologies. He also founded Xeragon, an RNA synthesis and bioinformatics firm acquired by Qiagen in 2002. He holds a master's degree in chemistry from the Swiss Federal Institute of Technology and is an author on several patents.

Banyai is a cofounder and director of the company and will maintain his board seat. He led the integration of Genome Compiler, which Twist acquired in 2016 and has overseen facilities expansions. Banyai previously served as VP of hardware at Complete Genomics. He holds a doctorate in optical science from the University of Arizona.

Jan 10, 2020

Oxford Nanopore Technologies: John O'Higgins, Clive Brown

John O'Higgins and Clive Brown have joined the board of directors of Oxford Nanopore Technologies, the company said this week. According to a regulatory filing, the appointments were made last September. Brown is the company's chief technology officer. O'Higgins, who joined the board as a non-executive director, is the former CEO of Spectris, an instrumentation and controls company. He holds non-executive roles at several other companies and is a member of the corporate advisory board of Great Ormond Street Hospital Charity in the UK.

Jan 10, 2020

Transplant Genomics: John Holman

Mansfield, Massachusetts-based Transplant Genomics has appointed John Holman as VP of Medical Affairs. He will replace Roy First, who will continue working as senior clinical advisor. Prior to TGI, Holman served as VP of Immunology and Translational Medicine at Quark Pharmaceuticals. He has also served as VP of clinical research at Myriad Genetics for three years. Prior to Myriad, Holman served as executive medical director as Astellas. 

Jan 09, 2020

Bio-Rad Laboratories: Dara Grantham Wright

Bio-Rad Laboratories has appointed Dara Grantham Wright as executive vice president of its clinical diagnostics group. She will replace John Hertia, who retired Dec. 31, 2019. Grantham Wright most recently served as VP and general manager of the protein and cell analysis biosciences division at Thermo Fisher Scientific. She has also held senior positions at Affymetrix, Boreal Genomics, and Becton Dickinson.

Jan 08, 2020

Genialis: Luka Ausec, Bruce Lefker

Genialis has promoted Luka Ausec to the position of chief discovery officer. He formerly served as director of projects for the San Ramon, California-based company. Genialis also added Bruce Lefker to its scientific advisory board. Lefker is a medicinal chemist with 30 years of experience working at Pfizer.

Jan 08, 2020

Genome Medical: Amy McLaughlin

Genome Medical has hired Amy McLaughlin as chief commercial officer. McLaughlin is leading sales, business development, marketing, and managed care for the telegenomics firm, which is in the process of expanding its commercial team. She previously served as senior vice president of business development for acute care management and staffing company Vituity.

Jan 08, 2020

Cytox: Ian Gilham

Cytox has appointed Ian Gilham its chairman of the board. He was CEO of Axis-Shield until Alere acquired the company in 2011. He also held positions at Amersham International, Abbott Laboratories, and GlaxoSmithKline. Gilham is currently non-executive chairman of Horizon Discovery, Genedrive, and Biosurfit and previously was chairman of Multiplicom and Elucigene. Oxford, UK-based Cytox develops noninvasive risk assessment and patient stratification tools for Alzheimer's disease and dementia. 

Jan 07, 2020

ArcherDx: Mark Massaro

ArcherDx has appointed Mark Massaro its CFO. He was most recently managing director and senior research analyst covering the diagnostics and life science tools sector at investment bank Canaccord Genuity. He also held corporate finance and financial reporting positions at Dell EMC and Fidelity Investments. 

Jan 06, 2020

NuProbe Global: Yingshuang Chai

NuProbe Global has named Yingshuang Chai CEO and chairman of the board of directors. Chai was cofounder and CEO of CarrierGene Biotech, a Chinese genetic testing firm that recently merged with NuProbe. He brings 20 years of experience in market operations, having served as the national clinical business director at Life Technologies China and national director of clinical strategy and development at Thermo Fisher China.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.